Pang‐Dian Fan

2.0k total citations · 1 hit paper
25 papers, 1.3k citations indexed

About

Pang‐Dian Fan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pang‐Dian Fan has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Pang‐Dian Fan's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (10 papers) and Lung Cancer Research Studies (5 papers). Pang‐Dian Fan is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (10 papers) and Lung Cancer Research Studies (5 papers). Pang‐Dian Fan collaborates with scholars based in United States, Japan and Spain. Pang‐Dian Fan's co-authors include Katerina Politi, Harold Varmus, Maureen F. Zakowski, Emily Schonfeld, William Pao, Helena A. Yu, Marc Ladanyi, Paul K. Paik, Charles M. Rudin and Stephen P. Goff and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Pang‐Dian Fan

25 papers receiving 1.2k citations

Hit Papers

Response to MET Inhibitor... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
    2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pang‐Dian Fan United States 15 679 617 596 276 113 25 1.3k
Ruth Riisnaes United Kingdom 15 667 1.0× 497 0.8× 786 1.3× 479 1.7× 108 1.0× 42 1.5k
Rajani Kanteti United States 21 446 0.7× 513 0.8× 761 1.3× 219 0.8× 178 1.6× 40 1.4k
Gayatry Mohapatra United States 14 486 0.7× 517 0.8× 743 1.2× 320 1.2× 210 1.9× 26 1.4k
Ulrike Tontsch-Grunt Austria 9 627 0.9× 413 0.7× 656 1.1× 129 0.5× 83 0.7× 20 1.4k
Analía Azaro Spain 18 295 0.4× 557 0.9× 569 1.0× 198 0.7× 107 0.9× 56 1.1k
C. Martin Curtis United States 15 624 0.9× 865 1.4× 952 1.6× 280 1.0× 78 0.7× 18 1.6k
Rajiv Bassi United States 19 373 0.5× 783 1.3× 925 1.6× 280 1.0× 113 1.0× 26 1.7k
Shigeki Nanjo Japan 22 1.0k 1.5× 824 1.3× 713 1.2× 317 1.1× 55 0.5× 54 1.6k
Beth Muir United States 11 820 1.2× 970 1.6× 1.3k 2.2× 436 1.6× 228 2.0× 11 2.4k
Chin‐Tung Chen United States 12 259 0.4× 574 0.9× 387 0.6× 152 0.6× 250 2.2× 24 988

Countries citing papers authored by Pang‐Dian Fan

Since Specialization
Citations

This map shows the geographic impact of Pang‐Dian Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pang‐Dian Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pang‐Dian Fan more than expected).

Fields of papers citing papers by Pang‐Dian Fan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pang‐Dian Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pang‐Dian Fan. The network helps show where Pang‐Dian Fan may publish in the future.

Co-authorship network of co-authors of Pang‐Dian Fan

This figure shows the co-authorship network connecting the top 25 collaborators of Pang‐Dian Fan. A scholar is included among the top collaborators of Pang‐Dian Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pang‐Dian Fan. Pang‐Dian Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steuer, Conor, Hidetoshi Hayashi, Wu‐Chou Su, et al.. (2025). Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Journal of Clinical Oncology. 43(25). 2816–2826. 3 indexed citations
2.
Kurmasheva, Raushan T., Peter J. Houghton, Ryuichi Nakamura, et al.. (2024). Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program. Cancer Research. 84(6_Supplement). 1088–1088. 1 indexed citations
3.
Hayashi, Hidetoshi, Helena A. Yu, Christina S. Baik, et al.. (2023). PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC. Annals of Oncology. 34. S1379–S1379. 1 indexed citations
4.
5.
Steuer, Conor, Hidetoshi Hayashi, Wu‐Chou Su, et al.. (2022). Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.. Journal of Clinical Oncology. 40(16_suppl). 9017–9017. 21 indexed citations
6.
Jänne, Pasi A., et al.. (2022). Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC.. Journal of Clinical Oncology. 40(16_suppl). TPS3161–TPS3161. 6 indexed citations
7.
Paik, Paul K., Pang‐Dian Fan, Besnik Qeriqi, et al.. (2022). Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. Journal of Thoracic Oncology. 18(4). 516–526. 22 indexed citations
8.
Sato, Hiroki, Daisuke Kubota, Huan Qiao, et al.. (2022). SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. JCO Precision Oncology. 6(6). e2200088–e2200088. 11 indexed citations
9.
Paik, Paul K., Linda S. Ahn, Andrew J. Plodkowski, Pang‐Dian Fan, & Charles M. Rudin. (2020). Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.. Journal of Clinical Oncology. 38(15_suppl). 9607–9607. 5 indexed citations
10.
Spraggon, Lee, Luciano G. Martelotto, Julija Hmeljak, et al.. (2017). Generation of conditional oncogenic chromosomal translocations using CRISPR–Cas9 genomic editing and homology‐directed repair. The Journal of Pathology. 242(1). 102–112. 20 indexed citations
11.
Song, Xiaoling, Pang‐Dian Fan, Udayan Guha, et al.. (2015). ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas. Cancer Research. 75(6). 1035–1045. 29 indexed citations
12.
Paik, Paul K., Alexander Drilon, Pang‐Dian Fan, et al.. (2015). Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery. 5(8). 842–849. 423 indexed citations breakdown →
13.
Politi, Katerina, Pang‐Dian Fan, Ronglai Shen, Maureen F. Zakowski, & Harold Varmus. (2009). Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Disease Models & Mechanisms. 3(1-2). 111–119. 60 indexed citations
14.
Politi, Katerina, Maureen F. Zakowski, Pang‐Dian Fan, et al.. (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors. Genes & Development. 20(11). 1496–1510. 353 indexed citations
15.
Fan, Pang‐Dian, Feng Cong, & Stephen P. Goff. (2003). Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.. PubMed. 63(4). 873–7. 22 indexed citations
16.
Fan, Pang‐Dian & Stephen P. Goff. (2000). Abl Interactor 1 Binds to Sos and Inhibits Epidermal Growth Factor- and v-Abl-Induced Activation of Extracellular Signal-Regulated Kinases. Molecular and Cellular Biology. 20(20). 7591–7601. 60 indexed citations
17.
Dorsch, Marion, Pang‐Dian Fan, Nika N. Danial, Paul B. Rothman, & Stephen P. Goff. (1997). The Thrombopoietin Receptor Can Mediate Proliferation without Activation of the Jak-STAT Pathway. The Journal of Experimental Medicine. 186(12). 1947–1955. 50 indexed citations
18.
Dorsch, Marion, Pang‐Dian Fan, Jakob Bogenberger, & Stephen P. Goff. (1995). TPO and IL-3 Induce Overlapping but Distinct Protein Tyrosine Phosphorylation in a Myeloid Precursor Cell Line. Biochemical and Biophysical Research Communications. 214(2). 424–431. 17 indexed citations
19.
Misra, R, et al.. (1991). The serum response factor is extensively modified by phosphorylation following its synthesis in serum-stimulated fibroblasts.. Molecular and Cellular Biology. 11(9). 4545–4554. 83 indexed citations
20.
Misra, Ravi, et al.. (1991). The Serum Response Factor Is Extensively Modified by Phosphorylation Following Its Synthesis in Serum-Stimulated Fibroblasts. Molecular and Cellular Biology. 11(9). 4545–4554. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruth Riisnaes Breakdown of academic impact, for papers by Rajani Kanteti Breakdown of academic impact, for papers by Gayatry Mohapatra Breakdown of academic impact, for papers by Ulrike Tontsch-Grunt Breakdown of academic impact, for papers by Analía Azaro Breakdown of academic impact, for papers by C. Martin Curtis Breakdown of academic impact, for papers by Rajiv Bassi Breakdown of academic impact, for papers by Shigeki Nanjo Breakdown of academic impact, for papers by Beth Muir Breakdown of academic impact, for papers by Chin‐Tung Chen
Rankless by CCL
2026